Health TrialsbyHealthPanel

Adenosine vs Diltiazem for Treatment of SVT in the ED

ConditionSupraventricular Tachycardia (SVT)
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-100
SponsorAnne E. Zepeski

About this trial

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients (18 years and older)

Diagnosis of acute, stable SVT in the emergency department

Disqualifiers

Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).

Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome

History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)

Severe bronchoconstrictive lung disease

Trial design

Design model

Single group

Treatments tested in this trial

  • adenosine

    Drug

    IV adenosine at standard doses for SVT (6 mg, 12 mg)

  • diltiazem

    Drug

    IV diltiazem at standard doses for SVT (0.25 mg/kg)

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: AdenosineActive comparator 1 intervention
Group B: DiltiazemActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Feasibility outcome

Patients with stable SVT are identified in the ED (Threshold \>90%)

Time frame
From enrollment to the end of ED encounter (up to 24 hours).
2

Feasibility outcome

Eligible participants who provide consent to participate (Threshold \>50%)

Time frame
From enrollment to the end of ED encounter (up to 24 hours).
3

Feasibility outcome

Participants who complete all study procedures (Threshold \>80%)

Time frame
From enrollment to the end of ED encounter (up to 24 hours).

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Anne E. Zepeski

Lead sponsor

University of Iowa

Sponsor institution

Source ClinicalTrials.gov
Apply now